At Boise Biologics Regenerative Medicine, were proud to offer Wolverine Peptide Therapy, a cutting-edge treatment combining BPC-157 and TB-500
On April 23, 2026 it came off the FDAs Category 2 do not compound list, and its one of seven peptides the FDAs Pharmacy Compounding Advisory Committee (PCAC) reviews on July 23-24, 2026 for 503A compounding eligibility
Developed with input from 228 experts, patient groups, and partner societies, the Roadmap identifies priorities across endocrine specialties and cross-cutting areas such as data, environment, health inequalities, and life-course transitions
Before treatment begins, our providers perform a comprehensive evaluation to determine whether peptide therapy is appropriate based on your health history, symptoms, and recovery goals
Therefore, we reiterate our stance outlined in the CY 2024 OPPS/ASC final rule with comment period that not all hospitals can produce a payer-specific negotiated charge in dollars that meets the definition of a standard charge. As indicated in the CY 2024 OPPS/ASC final rule with comment period, we finalized a requirement for hospitals to display an estimated allowed amount which would provide needed context, in dollars, for instances where the hospital's payer-specific negotiated charge is based on a percentage or algorithm
Essential for hospital patients with gastrointestinal disorders, bowel surgery, alcoholism, or chronic illness
